Marker Exploration Corporation
Marker X is dedicated to advancing early cancer detection and prevention through innovative blood-based screening technologies. Their mission is to provide precise, non-invasive, and personalized cancer screening services, utilizing cutting-edge proteomics and mass spectrometry techniques to identify cancer risks at an early stage, thereby improving patient outcomes and saving lives. Additionally, the company emphasizes the importance of early detection and prevention of chronic diseases such as diabetes and skin cancer, leveraging AI and proteomics analysis to support health monitoring and risk assessment.
Industries
Nr. of Employees
small (1-50)
Marker Exploration Corporation
112 Taipei City, Beitou District, Chengde Road, Section 7, No. 348, 5th Floor
Products
AI-assisted blood-based multi-cancer screening test
Diagnostic screening test analyzing plasma protein signatures from a small-volume blood sample and applying multi-analyte algorithms to estimate risk across multiple cancer types.
Mass spectrometry-based MRD monitoring assay
Mass spectrometry–based assay for minimal residual disease monitoring that detects and quantifies disease-specific protein signatures in blood to evaluate relapse risk.
AI-assisted blood-based multi-cancer screening test
Diagnostic screening test analyzing plasma protein signatures from a small-volume blood sample and applying multi-analyte algorithms to estimate risk across multiple cancer types.
Mass spectrometry-based MRD monitoring assay
Mass spectrometry–based assay for minimal residual disease monitoring that detects and quantifies disease-specific protein signatures in blood to evaluate relapse risk.
Services
Consultative design and laboratory execution of proteomics experiments, including sample processing, high-resolution mass spectrometry, data analysis, and delivery of analytical datasets for research or clinical validation.
End-to-end clinical workflow including point-of-collection blood draws via partner network, centralized laboratory analysis, and delivery of individualized reports with follow-up consultation.
Digital and community outreach materials that communicate risk factors for chronic disease, encourage participation in preventive screening, and provide guidance on screening options and follow-up.
Consultative design and laboratory execution of proteomics experiments, including sample processing, high-resolution mass spectrometry, data analysis, and delivery of analytical datasets for research or clinical validation.
End-to-end clinical workflow including point-of-collection blood draws via partner network, centralized laboratory analysis, and delivery of individualized reports with follow-up consultation.
Digital and community outreach materials that communicate risk factors for chronic disease, encourage participation in preventive screening, and provide guidance on screening options and follow-up.
Expertise Areas
- Proteomics-based biomarker discovery
- Blood-based early cancer screening
- Mass spectrometry analysis for diagnostics
- Multiplex immunoassays and assay validation
Key Technologies
- High-resolution mass spectrometry
- Top-down and bottom-up proteomics
- Multiplex immunoassays
- Liquid biopsy (blood-based biomarker assays)
News & Updates
Recent studies show that blood-based cancer detection methods are surpassing traditional screening techniques in accuracy.
Marker X Medical was recognized for its innovative contributions to medical technology and cancer screening.
Recent studies show that blood-based cancer detection methods are surpassing traditional screening techniques in accuracy.
Recent studies show that blood-based cancer detection methods are surpassing traditional screening techniques in accuracy.
Marker X highlights the importance of early, accurate, and non-invasive cancer screening technologies.
Research indicates that blood-based screening can detect cancer more accurately at an early stage.
Recent studies show that blood-based cancer detection methods are surpassing traditional screening techniques in accuracy.
Marker X Medical was recognized for its innovative contributions to medical technology and cancer screening.
Recent studies show that blood-based cancer detection methods are surpassing traditional screening techniques in accuracy.
Recent studies show that blood-based cancer detection methods are surpassing traditional screening techniques in accuracy.
Marker X highlights the importance of early, accurate, and non-invasive cancer screening technologies.
Research indicates that blood-based screening can detect cancer more accurately at an early stage.